U.S. Physical TherapyUSPH
USPH logo
Fair Value
US$93.67
Share price13 Jun
US$80.0514.5% undervalued intrinsic discount
Loading
1Y-8.70%
7D1.25%

Expanding Physical Therapy Demand Will Unlock New Market Potential

Analyst Consensus Target compiles analysts opinions to create narratives on stocks using the Analysts Consensus Price Target, forecasted revenue and earnings figures, as well as the transcripts of earnings calls.

Published
14 Sep 24
Updated
13 Jun 26
Views
129
Not Invested

Last Update 13 Jun 26

USPH: Hospital Alliances And Medicare Pricing Will Support Future Margin Upside

Analysts have lowered their price target on U.S. Physical Therapy to $90 from $103, citing somewhat lower profitability expectations and a higher projected net debt load following a mixed Q1 report.

What's in the News

  • From January 1, 2026 to March 31, 2026, U.S. Physical Therapy reported no share repurchases, with 0 shares bought for US$0 million under its existing buyback program (Key Developments).
  • The company has completed the repurchase of 81,322 shares for a total of US$5.57 million as part of the buyback that was announced on November 18, 2025, representing 0.53% of shares (Key Developments).
  • The recent buyback tranche update provides an additional data point on how management is using capital, even though there were no repurchases in the latest reported period (Key Developments).

Valuation Changes

  • Fair Value: Model fair value estimate is unchanged at $93.67 per share, even after the latest adjustments.
  • Discount Rate: Discount rate has risen slightly from 7.19% to 7.23%, implying a marginally higher required return in the model.
  • Revenue Growth: Revenue growth assumption remains effectively stable at about 7.71%.
  • Net Profit Margin: Net profit margin assumption is essentially unchanged at about 10.16%.
  • Future P/E: Future P/E assumption has edged up slightly from 17.31x to 17.33x, reflecting a very small change in the valuation multiple used.
8 viewsusers have viewed this narrative update

Key Takeaways

  • Rising patient demand, efficient operations, and acquisitions in key regions drive sustained revenue and margin growth, strengthening the company's earnings outlook.
  • Expansion into employer health services and potential regulatory benefits support diversified income streams and further improve future profitability.
  • Ongoing reimbursement pressures, labor cost inflation, digital disruption, industry consolidation, and regulatory scrutiny threaten margins, revenue growth, and long-term stability.

Catalysts

About U.S. Physical Therapy
    Operates and manages outpatient physical therapy clinics.
What are the underlying business or industry changes driving this perspective?
  • Sustained growth in patient volumes and record-high clinic visits per day, driven by the growing need for physical therapy among older adults and those with chronic conditions, positions the company for continued revenue growth, as healthcare demand demographics work in its favor.
  • Expanding industrial injury prevention and employer-based health services through organic growth and new contracts, including several large-scale opportunities not yet reflected in results, creates diversified and recurring revenue streams, reducing risk and supporting both top
  • and bottom-line growth.
  • Strategic cost efficiency initiatives-such as AI-driven clinical documentation, semi-virtualized front desk operations, and recruitment/retention technology-are beginning to materially lower operating and labor costs per visit, directly improving net margins and earnings potential.
  • Acquisition of high-performing clinics, especially in higher reimbursement geographies like New York, and a robust de novo and acquisition pipeline, provide further expansion of the patient base, enable contract pricing leverage, and increase average net rates, all supporting margin and earnings growth.
  • Favorable regulatory tailwinds, with Medicare reimbursement poised to shift from a multi-year headwind to a modest tailwind, create incremental EBITDA gains, while ongoing advocacy for PT-led musculoskeletal programs offers the potential for positive long-term reimbursement reform that could further lift future revenue and margins.
U.S. Physical Therapy Earnings and Revenue Growth

U.S. Physical Therapy Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

  • Analysts are assuming U.S. Physical Therapy's revenue will grow by 7.7% annually over the next 3 years.
  • Analysts assume that profit margins will increase from 1.0% today to 10.2% in 3 years time.
  • Analysts expect earnings to reach $100.0 million (and earnings per share of $3.55) by about June 2029, up from $7.7 million today.
  • In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 17.6x on those 2029 earnings, down from 130.1x today. This future PE is lower than the current PE for the US Healthcare industry at 23.4x.
  • Analysts expect the number of shares outstanding to grow by 0.1% per year for the next 3 years.
  • To value all of this in today's terms, we will use a discount rate of 7.23%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?
  • Ongoing healthcare reimbursement pressures-including the recent history of sequential Medicare cuts resulting in a cumulative $25 million annualized profit headwind-present a significant, long-term risk. Even if 2026 offers a modest rate increase, there is no guarantee it will persist, directly threatening future revenue and net earnings growth.
  • Rising labor costs and clinician shortages remain structural risks; although recent investments have reduced turnover and improved retention, management acknowledges staffing remains tight in several markets. Difficulty in recruiting or retaining clinicians as demand grows could squeeze operating margins and limit revenue scalability over time.
  • Accelerating digital and telehealth adoption in physical therapy poses a competitive threat, especially as large virtual PT providers expand into brick-and-mortar partnerships. If consumer or payer preferences shift toward digital-first models, U.S. Physical Therapy's clinic-centric model may see slower volume growth, affecting long-term top-line expansion.
  • Industry consolidation-including hospitals and larger health systems acquiring outpatient therapy clinics-could intensify competition and erode market share, leading to slower organic growth and potentially reduced revenues, especially as smaller competitors seek to scale up in response.
  • Heightened payer and regulatory scrutiny, such as the Michigan commercial payer policy change and persistent legal/regulatory compliance risks, could lead to lower net reimbursement rates, increased SG&A costs, and potential fines, undermining margins and earnings stability.

Valuation

How have all the factors above been brought together to estimate a fair value?

  • The analysts have a consensus price target of $93.67 for U.S. Physical Therapy based on their expectations of its future earnings growth, profit margins and other risk factors.
  • In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $984.2 million, earnings will come to $100.0 million, and it would be trading on a PE ratio of 17.6x, assuming you use a discount rate of 7.2%.
  • Given the current share price of $65.56, the analyst price target of $93.67 is 30.0% higher.
  • We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on U.S. Physical Therapy?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Read more narratives

Fair Value vs Share Price

US$93.67
vs US$80.0514.5% undervalued intrinsic discount
PastFuture0984m2015201820212024202620272029Revenue US$984.2mEarnings US$100.0m
7.7%
Revenue growth
10.2%
Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on U.S. Physical Therapy

  • Fair value estimate changes
  • Narrative and analyst updates
  • Key company announcements

Company analysis

Adequate balance sheet and fair value.

Market capUS$1.2b
PB2.7x
Estimated Growth7.5%
Dividend Yield2.3%
Full analysis

CEO & management

Christopher Reading
CEO
5.3yrs
CEO Tenure

Operates and manages outpatient physical therapy clinics.